“With the passing of the 20,000 patient milestone and with more than 98 percent of the implants still in place, we have achieved our initial goal of providing a less invasive option that would allow patients to go back to an active lifestyle while delaying the need for a joint replacement,” Steven Ek, COO of Arthrosurface, said in the release.
The Arthrosurface inlay resurfacing technology was developed to treat younger and more active patients, such as baby boomers, and is cleared for use in the knee, shoulder, hip and toe.
Read the Arthrosurface release on the 20,000 patient milestone.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
